Posts tagged ‘European Association of Urology’
Many European doctors enjoy a glass of good wine, so Bertrand Tombal’s metaphor that 2010 was a great year for advanced prostate cancer drugs was well received at the recent European Association of Urology Congress in Vienna.
Sally Church attended the meeting, and shared her thoughts on “the changing face of advanced prostate cancer” in a post on Pharma Strategy Blog.
According to Sally, one of the highlights of the meeting was the plenary presentation by Professor Johann de Bono of the Royal Marsden in the UK who discussed the new products that now exist or will soon be available for advanced prostate cancer.
Professor de Bono described how we now know more about Prostate Cancer and the fact that androgen receptor signaling remains active in advanced prostate cancer. Hormone therapy now works after chemotherapy, so the use of the term metastatic hormone refractory mHRPC is no longer valid.
He predicted that the we can expect the prostate cancer field to change in the next few years as we learn more about the molecular aspects of the disease and are better able to stratify patients.
With new products such as abiraterone, MDV3100 on the horizon and recent approvals for cabazitaxel, sipuleucel-T, multiple lines of treatment will be available to patients. The challenge according to Professor de Bono will be how to sequence them.
Further news on new product development in prostate cancer can be expected at AUA, ASCO and ESMO. With approval for abiraterone expected later this year, 2011 may be a Grand Cru year too! You can keep track of the latest developments in this market on Pharma Strategy Blog.
In a post that has provoked several comments, Pieter Droppert in a “letter from Vienna” discusses his observations about the sponsored sessions at the recent European Association of Urology Congress in Vienna.
In a meeting that featured a lot of innovative features such as webcasts of key presentations, the sponsored education sessions appeared too promotional.
Pieter’s blog post has prompted a debate as to whether these sessions were promotional or continuing medical education (CME), part of the Congress or not?
In the process it has raised the question of why European CME does not follow the same standards of independence and fair balance as US CME? Why do European medical congresses accept these type of quasi-promotional educational sessions?
As pharma marketing strategy consultants, we are all for promotional activities, but believe there needs to be a clear division between promotion and CME.
If you wish to enter the debate, and there’s nothing like a good bit of controversy to drive blog traffic, you can do so on Biotech Strategy Blog.
Sally Church on Pharma Strategy Blog will be providing live coverage of the annual European Association of Urology (EAU) Congress that starts in Vienna this weekend.
If you can’t join Sally at the meeting for a slice of schwarzwälder kirschtorte, then you can experience the meeting virtually as Sally aggregates all the live tweets, and contributes her own.
There are a lot of new products in the prostate cancer market. With new treatment options such as Dendreon’s sipuleucel-T, sanofi-aventis’ cabizatexel and JNJ’s abiraterone expected in the not too distant future, the meeting is bound to be interesting. We can also expect the latest news about new product development in bladder and renal cancer.
The Cover it Live widget on Sally’s blog will be aggregating all the tweets that use the conference hashtag #EAU11, so if you are unable to be in Vienna, you can follow what’s happening by clicking here.
Photo Werner Kunz via flickr
Icarus Consultants will be at the forthcoming European Urology Association annual meeting in Vienna, Austria from March 18-22, 2011.
If you are going to be in Vienna and would be interested in meeting up for Kaffee Und Kuchen, please contact us.
Incidentally, our favorite is a slice of Schwarzwälder Kirschtorte (Black Forest gateau).